Your browser doesn't support javascript.
loading
Associations between maternal characteristics and pharmaceutical treatment of gestational diabetes: an analysis of the UK Born in Bradford (BiB) cohort study.
Martine-Edith, Gilberte; Johnson, William; Hunsicker, Eugenie; Hamer, Mark; Petherick, Emily S.
Afiliação
  • Martine-Edith G; School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK.
  • Johnson W; School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK w.o.johnson@lboro.ac.uk.
  • Hunsicker E; School of Science, Loughborough University, Loughborough, UK.
  • Hamer M; Institute of Sport, Exercise and Health, Division Surgery Interventional Science, University College London, London, UK.
  • Petherick ES; School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK.
BMJ Open ; 11(11): e053753, 2021 11 03.
Article em En | MEDLINE | ID: mdl-34732497
ABSTRACT

OBJECTIVES:

To identify the maternal characteristics associated with pharmaceutical treatment of gestational diabetes mellitus (GDM).

DESIGN:

Prospective birth cohort study.

SETTING:

Bradford, UK.

PARTICIPANTS:

762 women from the Born in Bradford (BiB) cohort who were treated for GDM in a singleton pregnancy. BiB cohort participants were recruited from 2007 to 2010. All women booked for delivery were screened for GDM between 26 and 28 weeks of gestation using a 75 g 2-hour oral glucose tolerance test (OGTT). OUTCOME

MEASURE:

GDM treatment type lifestyle changes advice (lifestyle changes), lifestyle changes advice with supplementary insulin (insulin) and lifestyle changes advice with supplementary metformin (metformin).

RESULTS:

244 (32%) women were prescribed lifestyle changes advice alone while 518 (68%) were offered supplemental pharmaceutical treatment. The odds of receiving pharmaceutical treatment relative to lifestyle changes advice alone were increased for mothers who were obese (OR 4.6, 95% CI 2.8 to 7.5), those who smoked (OR 2.6, 95% CI 1.2 to 5.5) and had higher fasting glucose levels at OGTT (OR 2.1, 95% CI 1.6 to 2.7). The odds of being prescribed pharmaceutical treatment rather than lifestyle changes advice were lower for Pakistani women (OR 0.7, 95% CI 0.4 to 1.0)) than White British women. Relative to insulin treatment, metformin was more likely to be offered to obese women than normal weight women (relative risk ratio, RRR 3.2, 95% CI 1.3 to 7.8) and less likely to be prescribed to women with higher fasting glucose concentrations at OGTT (RRR 0.3, 95% CI 0.2 to 0.6).

CONCLUSIONS:

In the BiB cohort, GDM pharmaceutical treatment tended to be prescribed to women who were obese, White British, who smoked and had more severe hyperglycaemia. The characteristics of metformin-treated mothers differed from those of insulin-treated mothers as they were more likely to be obese but had lower glucose concentrations at diagnosis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Preparações Farmacêuticas / Diabetes Gestacional Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Pregnancy País/Região como assunto: Europa Idioma: En Revista: BMJ Open Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Preparações Farmacêuticas / Diabetes Gestacional Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Pregnancy País/Região como assunto: Europa Idioma: En Revista: BMJ Open Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido